Medicare GLP-1 Bridge Launches July 1: What Part D Plan Actuaries Need to Know

The $245 negotiated monthly net price for Wegovy and Zepbound, the $50 beneficiary copay that sits outside both the deductible and the true out-of-pocket cap, and the Humana-operated central processor running on LI NET infrastructure: these are the structural facts that define how the Medicare GLP-1 Bridge actually works when it opens July 1. CMS published full operational guidance in June, closing the informational gap that existed when earlier analyses addressed the $50 copay announcement and early structural unknowns from May. The picture that emerges for Part D plan actuaries is cleaner in one dimension and more uncertain in another.

From modeling GLP-1 utilization in Medicare Advantage plans over the past two years, the Bridge program’s eligibility criteria generate a pattern that is easy to miss if you read only the headline BMI threshold. Beneficiaries who qualify under the Bridge-specific comorbidity requirements, those with heart failure with preserved ejection fraction, stage 3a or higher chronic kidney disease, prior myocardial infarction, or previous stroke, are not a random cross-section of the Medicare population. They are its highest-cost subgroup. The Bridge design places the most expensive potential GLP-1 users outside the Part D benefit structure, leaving plan sponsors with zero drug cost risk for those members while the federal government absorbs the central processor payments directly. That is either an elegant cost-control design for plans or a temporary reprieve before the BALANCE model creates a structurally different exposure in 2027 or beyond. The actuarial modeling challenge is distinguishing between those two interpretations, and the BALANCE parameters that would help resolve it remain unpublished.

$50/mo

Fixed Beneficiary Copay (Outside Deductible and TrOOP)

$245

Negotiated 30-Day Manufacturer Net Price (WAC Difference Goes to CMS)

Dec 2027

Bridge Program End Date, When BALANCE or Legislative Action Must Follow

How the Bridge Pays: Central Processor Mechanics

The Medicare GLP-1 Bridge operates under Section 402 demonstration authority, which gives CMS the administrative flexibility to create a payment channel that runs parallel to, rather than within, the standard Part D benefit structure. Humana serves as the central processor, operating an enhanced version of the LI NET (Low-Income Net) infrastructure that currently handles Part D gap coverage for low-income beneficiaries awaiting enrollment. That infrastructure choice was deliberate: LI NET already connects to essentially every Medicare network pharmacy and has established claims-routing protocols that do not require plan-level integration.

The payment mechanics follow a four-step chain. A beneficiary with a qualifying prescription presents at any network pharmacy. The pharmacy collects $50. The claim routes to the Humana-operated central processor, which reimburses the pharmacy at no less than the drug’s wholesale acquisition cost minus the $50 copay plus a standard dispensing fee. The manufacturer then remits to CMS the difference between WAC and the $245 negotiated net price. The federal government absorbs the net program cost directly. No Part D plan touches this payment chain.

Three drug families qualify under Bridge coverage. Wegovy (semaglutide), manufactured by Novo Nordisk and including injectable formulations and the newer tablet form, carried a pre-deal list price of approximately $1,350 per month; the Bridge price is $245. Zepbound (tirzepatide), manufactured by Eli Lilly and restricted under the Bridge to the KwikPen formulation, carried a pre-deal list price above $1,080 per month; also $245 under the Bridge. Foundayo (orforglipron), Eli Lilly’s oral GLP-1 receptor agonist that received FDA approval April 1, 2026 and can be taken without food or water restrictions, enters with self-pay pricing starting at $149 per month for the lowest dose. Bridge pricing for Foundayo has not been publicly specified under the same $245 framework as the injectables, and that ambiguity matters for utilization projections given oral formulations’ historically higher adherence in commercial populations.

The program runs from July 1, 2026 through December 31, 2027, an 18-month demonstration window. CMS has not announced an extension mechanism, and there is no legislative authority currently in place to continue the Bridge past that date without further administrative action.

Eligibility Criteria: Narrower Than the Headlines Suggest

The Bridge’s eligibility criteria are meaningfully narrower than the BMI 27+ threshold that drove early utilization estimates. KFF estimated approximately 14 million Medicare beneficiaries carried overweight or obesity diagnoses as of 2020 claims data, and that figure has circulated widely as a proxy for Bridge-eligible population size. It is not the right denominator.

Qualifying criteria fall into two tiers. The first tier covers beneficiaries with a BMI of 30 or higher who also carry one of three specific comorbidities: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or above. The second tier covers beneficiaries with a BMI of 27 or higher who carry one of four cardiovascular or metabolic diagnoses: pre-diabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease. A beneficiary must satisfy both the BMI threshold and a qualifying comorbidity. BMI alone does not confer eligibility.

Applying these comorbidity screens to the 14 million top-line figure narrows the clinically eligible pool substantially. Based on published Medicare claims prevalence data for cardiovascular disease, CKD, and pre-diabetes in the BMI 27+ Medicare population, a reasonable first-order estimate places the clinically eligible pool at 6 to 9 million beneficiaries. That range carries meaningful uncertainty: claims-based prevalence data understates undiagnosed conditions (particularly pre-diabetes, where Medicare beneficiary screening rates have historically been inconsistent), and qualifying diagnoses may be documented at different rates across geography, specialty access, and socioeconomic status. Plans building utilization projections should model the eligible pool as a distribution, not a point estimate.

The Selection Effect: Who Qualifies and Why It Concentrates High-Cost Members

The eligibility architecture produces a specific risk-selection pattern that is actuarially significant for MA-PD plan sponsors. The comorbidities that qualify a beneficiary for Bridge coverage, heart failure with preserved ejection fraction, CKD stage 3a and above, prior MI, prior stroke, symptomatic PAD, are also the comorbidities that place Medicare beneficiaries in the highest-cost risk tiers under HCC coding. A beneficiary qualifying under the tier-one heart failure or CKD pathway typically carries a risk score above 1.8 and annual total cost of care well above $20,000. The Bridge’s design does not neutralize this population’s cost profile for the plan; it only removes the GLP-1 drug cost from the plan’s financial exposure. Medical costs, hospitalizations, and Part A utilization for these members remain fully within the plan’s financial risk.

This creates a two-part actuarial situation. In the near term, plans benefit from having GLP-1 obesity drug costs for their sickest members absorbed by the federal central processor rather than their Part D formulary. In the medium term, if GLP-1 therapy produces the cardiovascular risk reduction documented in the SELECT trial (a 20% relative risk reduction in major adverse cardiovascular events for semaglutide versus placebo in a population with BMI 27+ and prior cardiovascular disease), the Bridge may generate downstream medical cost reductions that flow to plan P&Ls through lower inpatient and outpatient utilization, but only after the 18-month demonstration window closes and only if those members remain enrolled in the same plan and maintain adherence.

Neither timing is modeled well by standard Part D bid actuarial frameworks, which do not capture cross-benefit-bucket cost interactions between Part D pharmacy and Part A/B medical costs within a single planning cycle.

Part D Plan Sponsor Obligations Under Full CMS Guidance

CMS’s June 2026 operational guidance clarifies several sponsor obligations that were ambiguous at the May announcement. The key points for plan actuaries:

Part D plans bear no risk for drugs dispensed under the Bridge. Sponsors do not need to opt in to the Bridge. They do not include Bridge claims in any Part D financial reporting. Bridge drugs do not count toward the plan’s gross covered prescription drug costs (GCPDC), do not affect the plan’s direct subsidy calculations, and do not interact with the plan’s risk corridor exposure. From a plan actuary’s standpoint, Bridge claims effectively do not exist within the Part D financial framework.

Standard formulary coverage for non-weight-loss GLP-1 indications must continue without interruption. Wegovy and Zepbound are approved for both weight management and cardiovascular risk reduction. Ozempic and Victoza are approved for type 2 diabetes management. Rybelsus is approved for type 2 diabetes. Trulicity remains in wide use for diabetes. Plans may not reduce formulary access to GLP-1 receptor agonists approved for diabetes or cardiovascular indications on the grounds that the obesity indications are now covered under the Bridge. Prior authorization requirements, step therapy protocols, and quantity limits for formulary GLP-1 drugs must remain consistent with standard clinical criteria and applicable ASOP No. 12 and federal formulary requirements.

Beneficiary appeal rights under Part D are preserved for formulary GLP-1 drugs. If a beneficiary disputes a coverage determination, step therapy requirement, or prior authorization denial for a GLP-1 prescribed for a formulary-covered indication, the standard Part D appeals process applies. The Bridge does not create a parallel appeals pathway, and plans should not redirect beneficiaries to Bridge processes for disputes about formulary coverage of diabetes or cardiovascular indications.

AMCP’s regulatory guidance published in March 2026, addressing the CMS FAQ on Bridge mechanics, confirmed that plans are permitted to communicate the Bridge program to beneficiaries as an available access pathway for obesity indications, but are not required to do so and cannot be penalized for failing to notify beneficiaries about a non-plan benefit.

The TrOOP and LIS Exclusion: Why Copay Accounting Matters

The Bridge’s exclusion of the $50 copay from true out-of-pocket spending has downstream actuarial effects that propagate through catastrophic phase projections, low-income subsidy calculations, and medical loss ratio reporting in ways that are not immediately obvious.

Under the standard Part D benefit redesigned by the Inflation Reduction Act, beneficiary out-of-pocket spending accumulates toward the $2,100 TrOOP cap (2026 figure). Once a beneficiary crosses the TrOOP threshold, they enter the catastrophic phase, where cost sharing falls to zero. The IRA redesign shifted the catastrophic phase risk heavily toward plan sponsors and reduced the federal reinsurance subsidy. Year-one Part D redesign data showed catastrophic phase utilization running approximately 22% above actuarial base cases, driven partly by beneficiaries reaching the TrOOP cap faster than models predicted. Bridge copays do not count toward TrOOP. A beneficiary filling GLP-1 drugs through the Bridge and other medications through their Part D formulary accumulates TrOOP only on the formulary drugs. For the subset of bridged beneficiaries whose other Part D drugs would have pushed them past the $2,100 threshold, the Bridge copay exclusion means they may remain in the initial coverage or coverage gap phase longer than they otherwise would, reducing plan liability at the catastrophic threshold.

This produces a directional reduction in plan-level catastrophic phase exposure for the Bridge-eligible population, but the magnitude depends on each plan’s member-level data. Actuaries should identify the subset of Bridge-eligible members who were previously forecast to reach the TrOOP cap, model their GLP-1 spend as now excluded from TrOOP accumulation, and recalculate the catastrophic phase enrollment rate accordingly. The reduction is real but likely modest in aggregate: Bridge-eligible members are high-cost patients who often carry enough other specialty pharmacy use to reach the TrOOP cap regardless of whether GLP-1s count toward it.

The LIS interaction is structurally similar. Low-income subsidy beneficiaries who fill drugs through the Bridge cannot apply LIS cost-sharing reductions to the $50 copay. For the dual-eligible population in particular, where LIS typically eliminates cost sharing entirely, the $50 copay represents a net new expense that the federal subsidy does not cover. Actuaries building D-SNP and dual-eligible plan bids should flag that the $50 Bridge copay may create access barriers for the lowest-income, highest-comorbidity Bridge-eligible members, potentially suppressing uptake in the population segment most likely to benefit clinically.

The BALANCE Model: Published, Paused, and Still Unclear on Key Parameters

CMS introduced the BALANCE (Beneficiary Access to Lifesaving Anti-obesity Necessary Coverage Enhancement) Model through the Innovation Center in December 2025. The model would have brought Part D plan sponsors into the GLP-1 obesity coverage chain in a way the Bridge deliberately avoids. CMS issued the Request for Applications to Part D sponsors in March 2026, set an April 20, 2026 application deadline, and announced the pause on April 21. The stated reason: the program failed to reach the 80% NAMBA-weighted enrollment threshold specified in Section 2.3.1 of the March 2026 RFA. The Bridge extension through December 31, 2027 followed as the immediate substitute.

What the RFA established about BALANCE before the pause remains relevant for 2028 bid planning, because CMS has not announced that BALANCE is cancelled. It is paused. The structural parameters CMS specified in the March RFA give a partial picture of what sponsor participation would have entailed. Enhanced Alternative plans and employer group waiver plans (EGWPs) would have paid a $50 copay per covered GLP-1 fill. Standard plans would have paid $125 per fill. Cost sharing in the catastrophic phase would have been eliminated for BALANCE-covered drugs. Plans would have been required to place all qualifying GLP-1 model drugs on formulary without tier discrimination. Risk corridor protection would have applied at 2.5% thresholds rather than the standard 5%, and only to plans exceeding one standard deviation above mean utilization nationally.

What the March RFA did not specify, and what remains unknown for 2028 bid planning: the pricing structure for manufacturers under BALANCE (whether the $245 Bridge manufacturer net price would carry over, or whether BALANCE would establish a different negotiated price); the utilization projection assumptions CMS would use to set the BALANCE benchmark rate; the eligibility criteria for BALANCE, which may differ from the Bridge’s comorbidity-gated thresholds; the formulary coverage scope, including whether oral GLP-1s like Foundayo would be covered under BALANCE or treated separately; and whether low-income subsidy beneficiaries would have cost-sharing eliminated or maintained at some positive level.

Plans filing 2028 Part D bids in mid-2027 will be required to do so before CMS is likely to finalize any of these parameters. The 2027 BALANCE launch timeline CMS referenced in April implies a new RFA in late 2026, a plan application window in early 2027, and enrollment design that becomes binding for plans before the 2028 bid submission deadline. For actuaries building 2028 models now, BALANCE must be treated as a scenario variable, not a known input, and the scenario should cover at minimum three states: BALANCE launches on schedule with broadly similar parameters to the March 2026 RFA; BALANCE launches with modified parameters that expand sponsor risk (broader eligibility, higher plan cost-sharing liability); or BALANCE is abandoned and the Bridge extends again through 2028, maintaining the current zero-plan-risk structure. Each scenario produces materially different catastrophic phase projections, formulary utilization assumptions, and net plan liability estimates for GLP-1 drugs as a class.

Utilization Projections: Three Estimates, Three Different Assumptions

Three published cost projections define the range that plan actuaries should bracket when building sensitivity scenarios. The Congressional Budget Office published its estimate in October 2024, before the Bridge was announced. CBO assumed standard Part D cost sharing, projected 12.5 million newly eligible beneficiaries, and modeled only 0.3 million (2%) actually using anti-obesity medications in year one, with a ten-year net federal cost of approximately $35 billion from 2026 through 2034. CBO’s per-user cost started at roughly $5,600 in 2026, declining to $4,300 by 2034 as IRA drug price negotiation provisions reduce the drug cost base. CBO’s assumption set predates both the $245 Bridge price and the $50 copay, which are substantially below the cost-sharing levels CBO modeled. Actual utilization under the Bridge should exceed CBO’s base case.

The JAMA Health Forum microsimulation published by Hwang et al. in April 2025 modeled broader coverage and produced a ten-year net Medicare cost of $47.7 billion, against gross drug spending of $65.9 billion and medical cost offsets of $18.2 billion (a 27.6% offset ratio). The Hwang model assumed 10% uptake with 40% long-term adherence and used a per-beneficiary annual net cost for semaglutide of approximately $8,412. The $245 monthly Bridge price, annualized at $2,940 net before the $50 monthly copay offset of $600, is roughly 65% below the Hwang model’s drug cost assumption. Lower drug costs and lower copays both point toward higher utilization than the Hwang simulation projected, widening the range of plausible federal expenditure upward.

STAT News reported in April 2026 that the $47.7 billion ten-year figure from the JAMA simulation has been widely cited in congressional discussions as the cost baseline for legislative options. The American Action Forum’s more granular per-user analysis derived a $1,743 annual federal cost per user at the $245 price after the $50 monthly copay offset, implying approximately $1.74 billion in annual program costs per million enrolled users. AAF modeled a mid-range scenario of 2.2 million new users, implying approximately $3.8 billion in annual steady-state cost. With a July 1, 2026 launch, the partial-year cost for fiscal year 2026 would be roughly half the annual steady-state figure.

Source	Eligible Population	Projected Year-1 Users	10-Year Net Federal Cost	Drug Cost Assumption
CBO (October 2024)	12.5 million	0.3 million (2%)	~$35 billion	Standard Part D cost sharing
JAMA/Hwang et al. (April 2025)	30 million cumulative	3 million (base case)	$47.7 billion net	~$8,412/year semaglutide
American Action Forum (November 2025)	~54.8 million Part D enrollees	2.2 million (mid-range)	~$3.8 billion/year at steady state	$245/month manufacturer net price

The gap between the CBO $35 billion estimate and the JAMA $47.7 billion estimate reflects fundamentally different uptake and adherence assumptions, not just different drug prices. The $50 copay represents a 96% reduction from Wegovy’s pre-Bridge list price and an 80% reduction from the $245 negotiated net price that manufacturers are absorbing. KFF survey data shows approximately half of current GLP-1 users describe the medications as difficult to afford. Removing the affordability barrier for the Medicare population, which has both higher obesity prevalence and lower average income than the commercially insured population, creates a demand environment that no pre-Bridge utilization model fully captures.

Building 2028 Bid Assumptions Before the Parameters Arrive

The fundamental modeling problem for 2028 bid actuaries is that two of the three BALANCE scenarios described above would require materially different formulary assumptions, drug cost trend factors, and catastrophic phase enrollment projections, and plans must file 2028 bids roughly six months before CMS is expected to finalize BALANCE parameters. This is not a gap that better research resolves; it is a structural timing mismatch between the Bridge program’s end date, the BALANCE launch timeline, and the Part D bid submission calendar.

A workable approach treats GLP-1 obesity coverage as a scenario-weighted expected value problem rather than a single-scenario projection. The three scenarios above (BALANCE launches on RFA terms, BALANCE launches with expanded sponsor risk, BALANCE fails and Bridge extends) each carry different probability weights that actuaries should document explicitly, with sensitivity testing around the key parameters: eligible population size, uptake rate, adherence persistence, drug cost per member per month, and medical cost offset timing. ASOP No. 25 standards for credibility and ASOP No. 41 standards for actuarial communications both apply to 2028 bid assumptions that incorporate BALANCE scenario probabilities; actuaries should document the scenario structure and weights in their supporting memoranda rather than burying them in aggregate trend factors.

For the RFA-terms BALANCE scenario, the March 2026 RFA gives enough structure to build a preliminary model. Enhanced Alternative and EGWP plans would absorb $50 per fill, with zero cost sharing in the catastrophic phase, uniform formulary placement, and risk corridor protection at the 2.5% threshold for outlier plans. The modeling question is what portion of the current Bridge-eligible population would transition into the plan’s formulary risk when BALANCE launches, at what utilization rate, and with what adherence profile. Plans with high proportions of Bridge-eligible members who are currently using the Bridge should assume that a meaningful fraction will continue GLP-1 therapy through BALANCE if it launches, creating an identifiable step-change in formulary GLP-1 costs at the 2028 transition point.

For the expanded-risk BALANCE scenario, the relevant assumption is that CMS recalibrates the BALANCE eligibility criteria to be broader than the Bridge’s comorbidity-gated requirements, potentially covering beneficiaries at BMI 27+ without the specific cardiovascular or renal qualifications the Bridge requires. That would substantially expand the eligible population and the plan-level drug cost exposure, because the lower-acuity beneficiaries who would be added under broader BALANCE criteria have not been pre-screened by the high-HCC comorbidity filter that characterizes the current Bridge-eligible population.

For the Bridge-extension scenario, actuaries should model 2028 as essentially a continuation of 2027: zero plan-level GLP-1 obesity drug cost, same comorbidity-gated eligibility, same $50 copay structure, same TrOOP and LIS exclusions. This is the simplest scenario to model but not necessarily the most likely; federal budget pressure and the political dynamics around GLP-1 access make the zero-plan-risk perpetual Bridge structurally unlikely as a permanent policy design.

The 2027 MA bid environment already reflects compressed margins across the NAMBA-weighted enrollment base, and plans that used aggressive utilization assumptions in their 2027 filings will have limited pricing room to absorb BALANCE-driven cost increases in 2028 bids without triggering rate increases that could accelerate the MA disenrollment trend that forced roughly 3 million beneficiaries to switch plans in 2026. Plans with high proportions of Bridge-eligible members should begin building the scenario framework now, before BALANCE parameters are published, so that the analytical structure is in place to incorporate the actual parameters quickly when they appear.

Why This Matters for Part D and MA-PD Plan Actuaries

The Bridge’s non-Part D design is the cleanest actuarial boundary CMS has drawn around a high-cost drug class in the program’s history. Plans have zero drug cost risk for the covered population through December 2027. That clarity simplifies 2027 bid construction. But the 18-month demonstration window is not long enough to produce adherence persistence data, comorbidity offset data, or uptake rate data that would be actuarially credible for 2028 bid purposes, and the BALANCE transition creates a structural discontinuity that sits exactly at the boundary of the current planning cycle.

Plans that treat 2027 as a clean baseline and wait for BALANCE parameters before building their 2028 scenario framework will find themselves behind. The analytical infrastructure for GLP-1 obesity coverage in a BALANCE-world Part D environment takes time to build: member-level Bridge utilization tracking, eligible population size monitoring, adherence persistence modeling, HCC interaction analysis, and catastrophic phase enrollment projections across the three BALANCE scenarios all require data inputs and modeling frameworks that benefit from being designed before the parameters that will populate them are finalized. The time to build that framework is now, while the Bridge is providing the first real-world Medicare GLP-1 utilization data the actuarial profession has ever seen.

Plans that use the Bridge’s 18-month window to build credible, scenario-aware GLP-1 modeling infrastructure will be positioned to file well-supported 2028 bids regardless of which BALANCE outcome materializes. Those that do not will be pricing under the same structural uncertainty that caused the original BALANCE model’s 80% enrollment threshold to fail in April 2026: uncertainty that plans rationally price conservatively, and conservative GLP-1 pricing in a competitive MA-PD market is a rate increase that beneficiaries will feel.